Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 7/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA4 | P22748 | 4/20 | 0.45 |
| ▸ | CA5A | P35218 | 4/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.41 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619733 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL313683 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL13928976 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL6230386 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL3972810 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL4619592 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL8089407 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL314060 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL314061 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL1686174 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0441948-A4 | SYNTHESIS OF STABLE, WATER-SOLUBLE CHEMILUMINESCENT 1,2-DIOXETANES AND INTERMEDIATES THEREFOR | — | 1992-06-03 | — | — | EP | claimed |
| EP-0441948-A1 | SYNTHESIS OF STABLE, WATER-SOLUBLE CHEMILUMINESCENT 1,2-DIOXETANES AND INTERMEDIATES THEREFOR | TROPIX, INC. (US) | 1991-08-21 | — | — | EP | claimed |
| WO-1991003479-A1 | SYNTHESIS OF STABLE, WATER-SOLUBLE CHEMILUMINESCENT 1,2-DIOXETANES AND INTERMEDIATES THEREFOR | TROPIX, INC. (US) | 1991-03-21 | — | — | WO | claimed |
| US-4956477-A | Synthesis of 1,2-dioxetanes | TROPIX, INC. (US) | 1990-09-11 | — | — | US | claimed |
| US-11667661-B2 | Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same | BIOMETRIX TECHNOLOGY INC (KR) | 2023-06-06 | — | — | US | disclosed |
| EP-4021510-A2 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | Medicortex Finland Oy (FI) | 2022-07-06 | — | — | EP | disclosed |
| US-20210300959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT COMPRISING THE SAME | BIOMETRIX TECHNOLOGY INC (KR) | 2021-09-30 | — | — | US | disclosed |
| WO-2021038125-A2 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | MEDICORTEX FINLAND OY (FI) | 2021-03-04 | — | — | WO | disclosed |
| WO-2015040467-A1 | VANCOMYCIN-SUGAR CONJUGATES AND USES THEREOF | Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) (IN) | 2015-03-26 | — | — | WO | disclosed |
| US-20100034735-A1 | TARGETED NANOPARTICLES FOR CANCER DIAGNOSIS AND TREATMENT | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT COMPRISING THE SAME | H1-3, H1-4, H1-5 | CYP2D6 695/4885THRB 4116/4885HSD17B10 3537/4885 |
| US-20100034735-A1 | TARGETED NANOPARTICLES FOR CANCER DIAGNOSIS AND TREATMENT | MKI67, KLK3, LGALS3 | CYP2D6 4393/4885THRB 2701/4885HSD17B10 3826/4885 |
| US-11667661-B2 | Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same | H1-3, H1-4, H1-5 | CYP2D6 398/4885THRB 4047/4885HSD17B10 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.